Evaluation of Liver Damage in Patients With Anorexia Nervosa by Blood Biomarker Analysis (NCT06262165) | Clinical Trial Compass
CompletedNot Applicable
Evaluation of Liver Damage in Patients With Anorexia Nervosa by Blood Biomarker Analysis
France19 participantsStarted 2024-02-16
Plain-language summary
The main goal of the BIocoLlection in Anorexia Nervosa-liver damage evaluation BILAN study the blood biomarkers associated with liver cytolysis.
Who can participate
Age range15 Years – 99 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria :
* Patient over 15 years old
* Diagnosis of Restricted Eating Disorders including Anorexia Nervosa according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
* Admission to Nantes University Hospital.
Exclusion Criteria :
* Chronic active viral hepatitis
* Hemochromatosis
* Other genetic, autoimmune.
* Treatment with a drug known to induce fatty liver disease (amiodarone, carbamazepine, tamoxifen, valproate, clozapine, anti-retrovirals) unless the dose has been stable for ≥ 3 months
* Excessive alcohol consumption (≥ 30 grams per day in men, ≥ 20 grams per day in women)
* Pregnant, parturient or breast-feeding women, persons deprived of liberty, adults under legal protection or unable to express their consent, persons not affiliated or not beneficiaries of a social security scheme, persons under guardianship or curators
What they're measuring
1
Identification of new blood biomarkers and hepatic cytolysis